Actively Recruiting
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Led by Chinese PLA General Hospital · Updated on 2026-01-02
100
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor. This open label, randomized, phase 2 study aims to evaluate the efficacy of Chidamide+Decitabine plus Anti-PD-1 Antibody and Brentuximab Vedotin plus Anti-PD-1 Antibody in transplant-ineligible or refused transplant diagnosedR/R cHL. The primary objective of the study is to evaluate progression-free survival.
CONDITIONS
Official Title
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- ECOG performance status less than 2
- Histological confirmation of classical Hodgkin lymphoma
- At least two prior lines of antitumor therapy
- Ineligible for or refused transplant
- Life expectancy of at least 3 months
- At least one measurable lymphoma lesion larger than 1 cm
- Completed previous treatment more than 4 weeks prior with recovery to grade 1 toxicity or less
- If previously had autologous hematopoietic stem-cell transplantation, it was more than 3 months ago
- Adequate marrow, liver, kidney, and heart function
You will not qualify if you...
- Prior treatment with the combination of Chidamide+Decitabine and anti-PD-1 antibody or Brentuximab Vedotin plus anti-PD-1 antibody
- Any autoimmune disease or history requiring corticosteroids or immunosuppressive drugs
- Serious uncontrolled medical disorders or active infections, especially pulmonary infection
- Active or recent (within 1 month) alimentary tract hemorrhage
- Prior organ transplant
- Pregnant or breastfeeding women
- Positive pregnancy test at enrollment or before treatment
- Compulsory detention for psychiatric or physical illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital
Beijing, China, 100853
Actively Recruiting
Research Team
H
Han wei dong
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here